PTU-116

SUBSTANTIAL CHEMOPREVENTATIVE EFFECT OF PIROXICAM IN MIN MICE INDEPENDENT OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA

doi:10.1136/gut.2011.239301.244

K M McCartney,* A Bennett, C Hawkey *University of Nottingham, Nottingham, UK*

Introduction Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to have chemopreventative properties against the development of colon polyps and cancer. We have previously shown that peroxisome proliferator activated receptor (PPAR) – alpha also acts to constrain polyp development in APC^{Min+/-} mice. As both eicosanoids and NSAIDs are ligands for PPARα we investigated the hypothesis that the effects of NSAIDs may be mediated through activation of PPARα by comparing the effect of the Cox1/2 inhibitor piroxicam in APC^{Min+/-} PPARα^{+/+} mice and APC^{Min+/-} PPARα^{-/-} mice.

Aims & Hypothesis The effect of genotype and piroxicam treatment on longevity, colon and small bowel polyp number and area were investigated. We hypothesise that piroxicam may be prolonging longevity in Min mice due to inhibition of Cox enzyme activity and a resultant activation of PPARα due to altered eicosanoid metabolism; a reduction in the number of polyps in the small and large bowel will result, inhibiting development of classic Min phenotype (anaemia, white paw and weight loss).

Methods Min mice of PPARα^{+/+} or PPARα^{-/-} genotype were fed standard chow (+ piroxicam 100 ppm or control). Mice were culled if they showed signs of white paw, weight loss >15% or tumour-induced prolapse, or at 1 year old if they

remained healthy. Large and small bowel tissue was removed, flushed and analysed for polyp number and area.

Results Mean age of death in PPAR^{-/-} control mice (n=22) was 22.31±1.20 (SEM) weeks and 47.67±1.69 (SEM) weeks in piroxicam treated mice (n=23, p<0.0001), PPAR^{+/+} control mice (n=22) was 24.21± 0.67 (SEM) weeks and 52.23±0.37 (SEM) weeks in piroxicam treated mice (n=23, p<0.0001)

The number of polyps in the mouse colon reduced significantly in piroxicam treated mice (age corrected). PPAR^{-/-} control (n=18) versus PPAR^{-/-} piroxicam (n=18, p=0.028), PPAR^{+/+} control (n=18) versus PPAR^{+/+} piroxicam (n=18, p=0.0048) There was no significant difference in total polyp area (age corrected). The number of polyps in the small bowel reduced significantly in piroxicam treated mice (age corrected). PPAR^{-/-} control (n=13) versus PPAR^{-/-} piroxicam (n=10, p=0.0001), PPAR^{+/+} control (n=11) versus PPAR^{+/+} piroxicam (n=11, p=0.0004) Total polyp area was significantly reduced in piroxicam treated mice (age corrected). PPAR^{-/-} control versus PPAR^{-/-} piroxicam p<0.0001, PPAR^{+/+} control versus PPAR^{+/+} piroxicam p<0.0001. Total polyp area (age corrected) was lower in PPAR^{+/+} control mice than in PPAR^{-/-} control mice (p=0.0489).

Conclusion Piroxicam at 100 ppm results in substantial prolongation of life, to an age greater than previously reported for Min mice. PPAR α status may influence small bowel polyp area but has minimal impact on the effect of piroxicam overall.

Competing interests None.

Keywords cox enzymes, NSAIDs, peroxisome proliferator activated receptor.